(+)-JQ1

Catalog No.S7110

(+)-JQ1 Chemical Structure

Molecular Weight(MW): 456.99

(+)-JQ1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for BRD4(1/2) in cell-free assays, binding to all bromodomains of the BET family, but not to bromodomains outside the BET family.

Size Price Stock Quantity  
USD 270 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

9 Customer Reviews

  • The BET protein inhibitor JQ1 reduces c-Myc expression and attenuates primary MCC cell proliferation. A, decreased c-Myc expression in MCC-3 and MCC-5 treated with JQ1 (800 nmol/L) for 72 hours by qRT-PCR and immunoblotting. The mRNA expression of target genes was normalized to that of MRPS2 and a value of 1.0 was assigned to the mRNA expression of target genes in the control group (means+SEM; **, P < 0.01 vs. control); b-actin was used as a loading control for immunoblotting.

    Cancer Res 2014 74(23), 7090-102. (+)-JQ1 purchased from Selleck.

    Immunohistochemical staining of xenograft tumor tissues. Immunohistochemical staining of xenograft tumor tissues with the indicated antibodies. p21-, p27-, p57-, and Ki67 positive cells (brown staining) were quantified at x400 magnification (meansSEM;**, P < 0.01;***, P < 0.001 vs. control); scale bars, 10 um.

    Cancer Res 2014 74(23), 7090-102. (+)-JQ1 purchased from Selleck.

  • (D) Effect of JQ1 on alterations of actin cytoskeleton in VEGF-induced HUVECs. The cells were pretreated with DMSO or JQ1 (100 nM) for 6 h, and stimulated with VEGF (10 ng/mL) for 12 h. F-actin (red) and nuclei (blue) were stained with phalloidin and DAPI, respectively. Representative images from 3 independent experiments.

    Sci Rep, 2016, 6:23770.. (+)-JQ1 purchased from Selleck.

    Sensitivity of BEZ235-resistant cells to JQ-1 using the MTT assay.

    Oncotarget, 2016, 6(7):5134-46.. (+)-JQ1 purchased from Selleck.

  • B. Repressed MCC-3 xenograft tumor growth upon combined treatment with MLN0128 and JQ1. Tumor bearing mice were treated with MLN0128 or vehicle at 1 mg/kg/day by oral gavage and JQ1 or vehicle at 50 mg/kg/day by i.p. injection for a period of 30 days. C. A more effective reduction of MCC-3 xenograft tumor growth in the group treated with combined therapy. Fold-reduction of tumor growth was calculated as average tumor growth of control group divided by average tumor growth of treatment group. Tumor growth was calculated as final average tumor volume minus initial average tumor volume in each group.

    Oncotarget, 2016, 7(6):6576-92.. (+)-JQ1 purchased from Selleck.

    Int J Stem Cells, 2018, 11(1):131-140. (+)-JQ1 purchased from Selleck.

  • JQ1 induces cell cycle arrest and apoptosis in Cal27 cells. (C) Cal27 cells were treated with JQ1 for 24 h and whole cell lysates were tested by western blot assays for the expression of cleaved-caspase-3. GAPDH was used as a loading control. (D) Apoptosis of Cal27 cells treated with JQ1 at 0 and 0.5 µM JQ1; *P<0.05 vs. control (the DMSO group)

    Oncol Rep, 2016, 36(4):1989-96.. (+)-JQ1 purchased from Selleck.

    immunofluorescence staining of BRD4 in ACC-LM and ACC-83 cells treated with JQ1 at the concentration of 1 µM for 24 h (×200).

    Biol Res, 2017, 50(1):19. (+)-JQ1 purchased from Selleck.

  • Effect of BET domain family inhibition on AMI damage in cardiomyocytes. (A) LDH and (B) CK-MB activity in the serum. #P<0.01 vs. sham group; @P<0.05 and &P<0.01 vs. AMI group. BET, bromodomain and extra-terminal; AMI, acute myocardial infarction; LDH, lactate dehydrogenase; CK-MB, creatine kinase MB isoenzyme.

    Exp Ther Med, 2015, 10(6):2319-2324.. (+)-JQ1 purchased from Selleck.

Purity & Quality Control

Choose Selective Epigenetic Reader Domain Inhibitors

Biological Activity

Description (+)-JQ1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for BRD4(1/2) in cell-free assays, binding to all bromodomains of the BET family, but not to bromodomains outside the BET family.
Features (+)-JQ1 is more effective than (-)-JQ1.
Targets
BRD4 (2) [1]
(Cell-free assay)
BRD4 (1) [1]
(Cell-free assay)
33 nM 77 nM
In vitro

(+)-JQ1 enantiomer binds directly into the Kac binding site of BET bromodomains. (+)-JQ1 (500 nM) binds BRD4 competitively with chromatin resulting in differentiation and growth arrest of NMC cells. (+)-JQ1 (500 nM) attenuates rapid proliferation of NMC 797 and Per403 cell lines as demonstrated by reduced Ki67 staining. (+)-JQ1 (500 nM) potently decreases expression of both BRD4 target genes in NMC 797 cells. (+)-JQ1 inhibits cellular viability with IC50 of 4 nM in NMC 11060 cells. [1] (+)-JQ1 results in robust inhibition of MYC expression in MM cell lines. (+)-JQ1 inhibits proliferating of KMS-34 and LR5 with IC50 of 68 nM and 98 nM, respectively. (+)-JQ1 (500 nM)-treated MM.1S cells results in a pronounced decrease in the proportion of cells in S-phase, with a concomitant increase in cells arrested in G0/G1. (+)-JQ1 (500 nM) results in pronounced cellular senescence by beta-galactosidase staining. (+)-JQ1 (800 nM) exposure leads to a significant reduction in cell viability among the majority of CD138+ patient-derived MM samples tested. [2] (+)-JQ1 inhibits growth of LP-1 cells with GI50 of 98 nM. (+)-JQ1 (625 nM) results in an increase in the percentage of LP-1 cells in G0/G1. (+)-JQ1 (500 nM) suppresses the expression of MYC, BRD4 and CDK9 in LP-1 cells. [3] (+)-JQ1 (1 μM) activates HIV transcription in latently infected Jurkat T cells. (+)-JQ1 (50 μM) stimulates predominantly Tat-dependent HIV transcription in both Jurkat and HeLa cells. (+)-JQ1 (5 μM) induces Brd4 dissociation enables Tat to recruit SEC to HIV promoter and induce Pol II CTD phosphorylation and viral transcription in J-Lat A2 cells. JQ1 enables Tat to increase CDK9 T-loop phosphorylation and partially dissociates P-TEFb from 7SK snRNP in Jurkat T cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
K1  NGf2UYdE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NGDKWXYzPTBxNUCwM|ExODBibl2= MnvlNlQwPDhxN{KgbC=> NYXLR2g{TE2VTx?= NVHPb3FOcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDDkc5NmNSCjbnSgeIlu\S1iZHXw[Y5l\W62IH3hco5meg>? MYKyOlcxPzh6MR?=
BCPAP Ml32R4VtdCCYaXHibYxqfHliQYPzZZk> M{G2ZVI2OC93MECvNVAxOCCwTR?= NEfjNIgzPC92OD:3NkBp Mn\5SG1UVw>? MXjpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy MYWyOlcxPzh6MR?=
K1  NVzyd|RQS2WubDDDfYNt\SCDc4PhfS=> M2ToSlI2OC93MECvNVAxOCCwTR?= M4\WclczKGh? MVjEUXNQ M4OyV4FzemW|dIOgZ4VtdCCleXPs[UBifCCJMD;HNUBxcGG|ZR?= M1O5elI3PzB5OEix
BCPAP NIWzXm5E\WyuIFP5Z4xmKEG|c3H5 MY[yOVAwPTByL{GwNFAhdk1? MXK3NkBp NHrROW9FVVOR NV;TeWRj[XK{ZYP0d{Bk\WyuIHP5Z4xmKGG2IFewM2cyKHCqYYPl MYGyOlcxPzh6MR?=
Hep3B NWLXOZVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;HToYxNTFyIN88US=> MlW5OUBl NVzEVIFwTE2VTx?= MWTJR|UxRTBwMEig{txO M4PEdFI3PTd3MU[3
HCCLM3 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPKNE0yOCEQvF2= NIXOXpE2KGR? M{i4U2ROW09? NF6zbmtKSzVyPUCuNVQh|ryP MXeyOlU4PTF4Nx?=
HuH7 MmTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVGwMVExKM7:TR?= MmjkOUBl NGTaW4xFVVOR NXXlXWg2UUN3ME2wMlIyKM7:TR?= MnP3NlY2PzVzNke=
HepG2 M4Xa[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LYV|AuOTBizszN NEXKdlM2KGR? Mmf3SG1UVw>? NULXV4NoUUN3ME2wMlM1KM7:TR?= NFz5XZYzPjV5NUG2Oy=>
SMMC7721 NHzWR3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1n2TVAuOTBizszN Mne0OUBl MYDEUXNQ MXnJR|UxRTBwNEGg{txO NGXPSZozPjV5NUG2Oy=>
BEL7402 MnrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TaOFAuOTBizszN Ml\6OUBl NWq5e|hZTE2VTx?= NIDhR3FKSzVyPUCuOFch|ryP M2O5elI3PTd3MU[3
MHCC97H M2PmZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHr5eoUxNTFyIN88US=> NYmzd3ZKPSCm M4H6N2ROW09? MormTWM2OD1yLkSxJO69VQ>? NV;M[ItSOjZ3N{WxOlc>
Hep3B M1fjcmNmdGxiQ4njcIUhSXO|YYm= M2C5SlAvOS9yLkWvNk42KM7:TR?= M{W3VlQ5KGh? NWXuS|Q4TE2VTx?= M4DnOoxm[WS|IITvJIEhe3Wkc4ThcpRq[WxiYXPjeY12dGG2aX;uJI9nKEiFQzDj[YxteyCrbjDzeYIuTzFicHjhd4XDqA>? MlPhNlY2PzVzNke=
HCCLM3 NYXRdpk3S2WubDDDfYNt\SCDc4PhfS=> NWmz[3NtOC5zL{CuOU8zNjVizszN MonzOFghcA>? MYXEUXNQ M1;rZYxm[WS|IITvJIEhe3Wkc4ThcpRq[WxiYXPjeY12dGG2aX;uJI9nKEiFQzDj[YxteyCrbjDzeYIuTzFicHjhd4XDqA>? NV\6XYdCOjZ3N{WxOlc>
Hep3B Ml3iRZBweHSxc3nzJGF{e2G7 MoXHNE4yNzBwNT:yMlUh|ryP NY\v[5U{PDhiaB?= NWewZ3FXTE2VTx?= MV;hZ5RqfmG2ZYOgZ4F{eGG|ZT2zJIFv\CClYYPwZZNmNTliZYjwdoV{e2mxbjDhcoQhcW6mdXPl[EBRSVKSIHPs[YF3[WenIHHzJJdmdGxiYYOgZ5l1d2Oqcn;t[UBkKHKnbHXhd4UhcW62bzD0bIUh[3m2b4DsZZNuKG[{b32gcYl1d2Oqb37kdoli NEjkS2UzPjV5NUG2Oy=>
HCCLM3 NXTXTHl3SXCxcITvd4l{KEG|c3H5 MnSxNE4yNzBwNT:yMlUh|ryP MUW0PEBp MXPEUXNQ M{XxOoFkfGm4YYTld{Bk[XOyYYPlMVMh[W6mIHPhd5Bie2VvOTDlfJBz\XO|aX;uJIFv\CCrbnT1Z4VlKFCDUmCgZ4xm[X[jZ3WgZZMhf2WubDDhd{BkgXSxY3jyc41mKGNicnXs[YF{\SCrboTvJJRp\SCleYTvdIxie21iZoLvcUBucXSxY3jvcoRzcWF? NYnhcZdoOjZ3N{WxOlc>
A549 M3q3fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;mbZFOOC5zLUGwJO69VQ>? NIfJbpg4OiCq MVnpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> Mn\GNlY1OTV{MkW=
H157 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDpO3VNOC5zLUGwJO69VQ>? MmK4O|IhcA>? NUm5UYNQcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NGnMNI0zPjRzNUKyOS=>
H1299 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13W[VAvOS1zMDFOwG0> MoHlO|IhcA>? NX3FXG81cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NH7vfIkzPjRzNUKyOS=>
A549 NXfzSVFPTnWwY4Tpc44hSXO|YYm= NUX0UmwzOS9{LkWvOUDPxE1? MYWxNkBp MoG1xsB4\WGtbImg[IVkemWjc3XkJGJkdC1{IHzleoVtew>? NVT4W21jOjZ2MUWyNlU>
H1299 MVHGeY5kfGmxbjDBd5NigQ>? MWOxM|IvPS93IN88US=> M4naN|EzKGh? NX76VWZEyqC5ZXHrcJkh\GWlcnXhd4VlKEKlbD2yJIxmfmWucx?= NWq5Z|VpOjZ2MUWyNlU>
H157 M33RS2Z2dmO2aX;uJGF{e2G7 NHLvO2cyNzJwNT:1JO69VQ>? NHv5OnkyOiCq NUD1bG5W\GWlcnXhd4VlKESUNDDlfJBz\XO|aX;u NG\IWHgzPjRzNUKyOS=>
H1299 M{L6PGZ2dmO2aX;uJGF{e2G7 MUCxM|IvPS93IN88US=> MlTzNVIhcA>? M2LNfYRm[3KnYYPl[EBFWjRiZYjwdoV{e2mxbh?= MkDXNlY1OTV{MkW=
C8161 NE\oWWlE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MUOwMVIh|ryP MV:0JIQ> NHHP[pVFVVOR M4WzOoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NUDZU2dEOjZ|OUeyNlM>
Mel285 NYT1U5JqS2WubDDWbYFjcWyrdImgRZN{[Xl? MoLNNE0zKM7:TR?= M{eyTlQh\A>? MnTESG1UVw>? NIjtU5Nl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NIn1cVczPjN7N{KyNy=>
Mel290 NVHtSVJHS2WubDDWbYFjcWyrdImgRZN{[Xl? MmWyNE0zKM7:TR?= NF33W2g1KGR? MVXEUXNQ NVjQRXJx\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NXf0[IdYOjZ|OUeyNlM>
92.1 MofyR4VtdCCYaXHibYxqfHliQYPzZZk> M1vLXFAuOiEQvF2= MUi0JIQ> M2DZW2ROW09? MVnk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NY\DRYtsOjZ|OUeyNlM>
Omm1.3 M3OwUmNmdGxiVnnhZoltcXS7IFHzd4F6 MX2wMVIh|ryP NXG3XGZCPCCm NV7XN2N1TE2VTx?= MVTk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NGPPc3QzPjN7N{KyNy=>
Mel202 M2XvNmNmdGxiVnnhZoltcXS7IFHzd4F6 MmHuNE0zKM7:TR?= NGTSSoc1KGR? NWLTNm8{TE2VTx?= Ml:1[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ Mn\zNlY{QTd{MkO=
Mel270 MnTqR4VtdCCYaXHibYxqfHliQYPzZZk> NWL5eXh6OC1{IN88US=> NVzhWWNLPCCm M1KzdmROW09? NHrB[5Nl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MWOyOlM6PzJ{Mx?=
Omm1 M17sRmNmdGxiVnnhZoltcXS7IFHzd4F6 NYDRVZdqOC1{IN88US=> MnHvOEBl MlzrSG1UVw>? NVG5S3VH\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MVmyOlM6PzJ{Mx?=
92.1 MkLTRZBweHSxc3nzJGF{e2G7 NH6xcmk2ODBibl2= MX60PEBp Mk\HSG1UVw>? M3TBVIlv\HWlZYOgZZBweHSxc3nz MYWyOlM6PzJ{Mx?=
Omm1.3 NF\uUFhCeG:ydH;zbZMhSXO|YYm= NHzaSFc2ODBibl2= NGq1R4U1QCCq NYr6Nm9LTE2VTx?= NF\OO2hqdmS3Y3XzJIFxd3C2b4Ppdy=> MWCyOlM6PzJ{Mx?=
92.1 MUHD[YxtKEO7Y3zlJGF{e2G7 NXW1fnVWPTByIH7N MlnLNlQwPDhxN{KgbC=> M12wRWROW09? NWfmSoFwcW6mdXPld{B1cGViY3XscEBi[2O3bYXsZZRqd25iYYSgd5VjNUdzwrC= NVKzVWY4OjZ|OUeyNlM>
Omm1.3 NV\4OG9{S2WubDDDfYNt\SCDc4PhfS=> M1PjPVUxOCCwTR?= NXLyNoRGOjRxNEivO|IhcA>? MlHySG1UVw>? MoDsbY5lfWOnczD0bIUh[2WubDDhZ4N2dXWuYYTpc44h[XRic4XiMWcyyqB? NHPJVGgzPjN7N{KyNy=>
A549 NYr3Slh[TnWwY4Tpc44hSXO|YYm= NF\BTlEyODBxNECwM|ExODBibl2= NInZemgzPCCq MV;1dJJm\3WuYYTld{BidmRiYXP0bZZifGW|IGPJVnQy NH3Pe3MzPjJzMkG5PS=>
MCF-7 M4Kx[WZ2dmO2aX;uJGF{e2G7 M13t[|ExOC92MECvNVAxOCCwTR?= MUeyOEBp M2jyNpVxemWpdXzheIV{KGGwZDDhZ5RqfmG2ZYOgV2lTXDF? M{\3SVI3OjF{MUm5
HEK293 MUfGeY5kfGmxbjDBd5NigQ>? Ml3RNVAxNzRyMD:xNFAxKG6P NIm3[YwzPCCq Mk\BeZBz\We3bHH0[ZMh[W6mIHHjeIl3[XSnczDTTXJVOQ>? NVX1d45sOjZ{MUKxPVk>
858 NVuyUmdQS2WubDDWbYFjcWyrdImgRZN{[Xl? MVqwMVEh|ryP MUW1JIQ> MmLhSG1UVw>? NEG2cJRl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NWHyWHZROjZ{ME[zN|M>
DDR2L63V Ml3iR4VtdCCYaXHibYxqfHliQYPzZZk> MoDYNE0yKM7:TR?= M3XhflUh\A>? MkPxSG1UVw>? NVfYXJd1\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NVj4Roc1OjZ{ME[zN|M>
BE(2)-C MUfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M4DqRVEh|ryP M{nWflEuPCCm MWfk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHlic3nncolncWOjboTsfS=> M4rS[FI3ODZ5NE[0
IMR-32 NIm5c|dE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M{\xU|Eh|ryP MlLiNU01KGR? NXLlXm5U\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJNq\26rZnnjZY51dHl? M4f3XVI3ODZ5NE[0
JF M3OzfWNmdGxiVnnhZoltcXS7IFHzd4F6 NVe4SHNTOSEQvF2= MX6xMVQh\A>? M1PpdIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDzbYdvcW[rY3HueIx6 MoLhNlYxPjd2NkS=
BE(2)-M17 M3iwO2NmdGxiVnnhZoltcXS7IFHzd4F6 NImwXHUyKM7:TR?= NG\qWXUyNTRiZB?= MUXk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHlic3nncolncWOjboTsfS=> M2TUelI3ODZ5NE[0
SK-N-SH NV;GPVE1S2WubDDWbYFjcWyrdImgRZN{[Xl? MkHhNUDPxE1? NITvUZkyNTRiZB?= NFn5OpJl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>? MUmyOlA3PzR4NB?=
SK-N-DZ  MlK2R4VtdCCYaXHibYxqfHliQYPzZZk> MVuxJO69VQ>? Mk[3NU01KGR? MojO[IVkemWjc3XzJINmdGxidnnhZoltcXS7IIPp[45q\mmlYX70cJk> MkjxNlYxPjd2NkS=
HMC-1.1  NFnlSlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;KUms2NTVyMECgcm0> M{nOdFQ5KGh? NGOycYJFVVOR M4LrT4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M1nobFI3ODV3M{Cz
HMC-1.2 M2raTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmizOU02ODByIH7N MVO0PEBp NFu5bmlFVVOR NFPLWHpqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MYCyOlA2PTNyMx?=
ROSA KIT WT  MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXvPHk2NTVyMECgcm0> MoPIOFghcA>? MmnLSG1UVw>? M2nOcolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MYSyOlA2PTNyMx?=
ROSA KIT D816V M4jQ[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjBVXc2NTVyMECgcm0> NUTTVYc{PDhiaB?= MXPEUXNQ M3;XSolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NVLtdYNDOjZyNUWzNFM>
HMC-1.1  M2W5ZmFxd3C2b4Ppd{BCe3OjeR?= NYrrU4lwOjByLUWwNFAhdk1? M{Luc|Q5KGh? NGi0dmZFVVOR MlHlbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NE\OSWwzPjB3NUOwNy=>
HMC-1.2 MXnBdI9xfG:|aYOgRZN{[Xl? MYCyNFAuPTByMDDuUS=> MoHqOFghcA>? MUfEUXNQ NVHScmFCcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MVqyOlA2PTNyMx?=
ROSA KIT WT  Mk\mRZBweHSxc3nzJGF{e2G7 MkPoNlAxNTVyMECgcm0> MlvvOFghcA>? NIDUd5hFVVOR M363Oolv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NWTUXmNOOjZyNUWzNFM>
ROSA KIT D816V NETaW45CeG:ydH;zbZMhSXO|YYm= M1XJT|IxOC13MECwJI5O MXG0PEBp MkLRSG1UVw>? M1n0cIlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NYq0RlR{OjZyNUWzNFM>
494H MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrXO|IhcA>? NFv5RVlFVVOR NIrR[IFKSzVyPUCuNVIzyrFyLkCwOEDPxE1? NELuWoEzPTl2NEW2Oi=>
493H NVX3NFB6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYW3NkBp Mlq5SG1UVw>? MYLJR|UxRTBwMES3xtExNjByOTFOwG0> MVGyOVk1PDV4Nh?=
716H MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3m5W|czKGh? MkDRSG1UVw>? MmfpTWM2OD1yLkKxNuKyOC5yM{Sg{txO MlXONlU6PDR3Nk[=
148I NGK2WoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjF[|E4OiCq MmfxSG1UVw>? M3\ZUmlEPTB;MD6yPFTDuTBwMEO1JO69VQ>? M{jTSVI2QTR2NU[2
98Sc NX3Db4NYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\4N2o4OiCq NH;UTJdFVVOR MUjJR|UxRTBwMUG1xtExNjByNDFOwG0> M4nGWVI2QTR2NU[2
89R MlP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVi0V3dbPzJiaB?= M{XFVmROW09? NYnU[YpZUUN3ME2wMlEzPsLzMD6wNFMh|ryP NEnWR2szPTl2NEW2Oi=>
494L Mn\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fBNFczKGh? NXLpb2ROTE2VTx?= M4rTWWlEPTB;MD6zNVfDuTBwMEGyJO69VQ>? MUmyOVk1PDV4Nh?=
493L NHftSppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzaO|IhcA>? MXHEUXNQ MVzJR|UxRTBwMEWwxtExNjBzMTFOwG0> MkDLNlU6PDR3Nk[=
148L MmrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPLO|IhcA>? NITzbZFFVVOR NF\6VlVKSzVyPUCuNVQ3yrFyLkCxO{DPxE1? MnXsNlU6PDR3Nk[=
98L NWrCeoEzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF[5XFQ4OiCq NUmzdGVoTE2VTx?= M1LKe2lEPTB;MD6zNFnDuTBwMEK5JO69VQ>? NEPEO2QzPTl2NEW2Oi=>
OS17 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrOfnk4OiCq NIrHUYVFVVOR NYDFeGw3UUN3ME2wMlA4QcLzMD6wNFMh|ryP M1fVdFI2QTR2NU[2
OS9 NXHMe4dsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWq2UpVYPzJiaB?= MXLEUXNQ M1fVR2lEPTB;MD60NFbDuTBwMEK4JO69VQ>? M4PtfFI2QTR2NU[2
MG63 M{PDUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFm4Om04OiCq MYPEUXNQ M3fnT2lEPTB;MD6xNVTDuTBwMEK1JO69VQ>? Mm\PNlU6PDR3Nk[=
SAOS2 NHLpPHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGC3[|Y4OiCq Mom0SG1UVw>? M{jJcWlEPTB;MD6yNVfDuTBwMECzJO69VQ>? NEfjOIMzPTl2NEW2Oi=>
U2OS NVf3SYN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\KO3UzPzJiaB?= NWr6NWNoTE2VTx?= NVjmWHdYUUN3ME2wMlE6QMLzMD6wNFgh|ryP NVjySHVJOjV7NES1OlY>
SJSA-1 M{HxW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jsbVczKGh? M2Gz[mROW09? NWjlVHRsUUN3ME2wMlExOMLzMD6wNVAh|ryP NHrPN4ozPTl2NEW2Oi=>
494H NYHuT3VUSXCxcITvd4l{KEG|c3H5 M{XDblAvOjVxMD61M|EvOCEQvF2= NVj5[pZ5OjRiaB?= M1PvXGROW09? M3vEbYlv[3KnYYPld{Bt\X[nbIOgc4Yh[2ynYY\l[EBk[XOyYYPlMVPDqA>? M33nU|I2QTR2NU[2
148I Mm\XRZBweHSxc3nzJGF{e2G7 NHLObGkxNjJ3L{CuOU8yNjBizszN MWiyOEBp NH;1eXBFVVOR NXHoZnA6cW6lcnXhd4V{KGyndnXsd{Bw\iClbHXheoVlKGOjc4Dhd4UuO8Li NUmx[2ZCOjV7NES1OlY>
OS17 NVK0fVFXSXCxcITvd4l{KEG|c3H5 NFXxOWMxNjJ3L{CuOU8yNjBizszN MWqyOEBp MoPYSG1UVw>? NF;VflJqdmO{ZXHz[ZMhdGW4ZXzzJI9nKGOuZXH2[YQh[2G|cHHz[U0{yqB? NVrheVNsOjV7NES1OlY>
494H NFzBeIdCeG:ydH;zbZMhSXO|YYm= NU\VRlJlOeLCid88US=> MXK0PEBp NYH3T|V4TE2VTx?= M4X2Xolv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3nncolncWOjboTsfS=> MkDSNlU6PDR3Nk[=
148I NHvqOphCeG:ydH;zbZMhSXO|YYm= M2W3RVHjiIoQvF2= NVHVU5pTPDhiaB?= MXTEUXNQ MWrpcoR2[2W|IHPlcIwh[XCxcITvd4l{KHOrZ37p[olk[W62bIm= NWrRWIduOjV7NES1OlY>
OS17 MkD5RZBweHSxc3nzJGF{e2G7 Mm\qNgKBkc7:TR?= NHzCSVM1QCCq NWPvUo1oTE2VTx?= Mne2bY5lfWOnczDj[YxtKGGyb4D0c5NqeyC|aXfubYZq[2GwdHz5 MnezNlU6PDR3Nk[=
MOLM13 MnPORZBweHSxc3nzJGF{e2G7 MVuyOVAhdk1? M3nwb|Q5KGh? M3LON2ROW09? MXrpcoR2[2W|IIPp[45q\mmlYX70cJkh[XCxcITvd4l{KGOxdILlZZRu\W62IIfpeIgheXWrenHyeIlvcWJ? NYfu[lBFOjVyNUO4NlU>
MV4-11  MXfBdI9xfG:|aYOgRZN{[Xl? MlftNlUxKG6P NWDGXoMzPDhiaB?= MmfSSG1UVw>? NF3uV49qdmS3Y3XzJJNq\26rZnnjZY51dHliYYDvdJRwe2m|IHPveJJm[XSvZX70JJdqfGhicYXpfoFzfGmwaXK= M4PQWVI2ODV|OEK1
MOLM13 NVm5fXpKTnWwY4Tpc44hSXO|YYm= MnnONlUxKG6P MYOyOEBp NX;NelFvTE2VTx?= Mlnr[Y5p[W6lZYOgdZVqgmG{dHnubYIucW6mdXPl[EBud3KnIICyNUwhSkmPLDDhcoQh[2ynYY\l[EBRSVKS M3;xRlI2ODV|OEK1
MV4-11  MkG5SpVv[3Srb36gRZN{[Xl? MlXvNlUxKG6P NGDUflMzPCCq NHP3VVJFVVOR MVLlcohidmOnczDxeYl7[XK2aX7pZk1qdmS3Y3XkJI1wemVicEKxMEBDUU1uIHHu[EBkdGWjdnXkJHBCWlB? MnLaNlUxPTN6MkW=
MOLM13 NYnEO4lCSXCxcITvd4l{KEG|c3H5 NUnl[2pqOjVyIH7N NVfhTVVnPDhiaB?= MnPnSG1UVw>? MWfpcoR2[2W|IIPp[45q\mmlYX70cJkh[XCxcITvd4l{KGOxdILlZZRu\W62IIfpeIgheG:wYYTpcolj Mni5NlUxPTN6MkW=
MV4-11  M{fYU2Fxd3C2b4Ppd{BCe3OjeR?= NVfVbGpvOjVyIH7N NEPkcWM1QCCq NGXLSJpFVVOR NU[2eG5{cW6mdXPld{B{cWewaX\pZ4FvfGy7IHHwc5B1d3OrczDjc5Rz\WG2bXXueEB4cXSqIIDvcoF1cW6rYh?= M3f3T|I2ODV|OEK1
Hela M4TKZWNmdGxiVnnhZoltcXS7IFHzd4F6 NWrRUm1kOC13MECgcm0> M4nNWVczKGh? NIDSfG1FVVOR MXnk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NVPGW5Z2OjVyMEmyPVU>
HBL-1 NUfU[GZqS2WubDDWbYFjcWyrdImgRZN{[Xl? M4roflAuPTByIH7N NF:1VXA4OiCq NUe4bHhjTE2VTx?= MWHk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NGjVS4EzPTByOUK5OS=>
HLY-1 MXPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NX23N5Q{OC13MECgcm0> MmfGO|IhcA>? MWXEUXNQ NXfqUIU4\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NI\KXXAzPTByOUK5OS=>
OCI-Ly3 NV3XS|FYS2WubDDWbYFjcWyrdImgRZN{[Xl? MmrHNE02ODBibl2= M1rseFczKGh? MVfEUXNQ MYrk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NYe3cnlIOjVyMEmyPVU>
OCI-Ly10 Ml7tR4VtdCCYaXHibYxqfHliQYPzZZk> NIfGemMxNTVyMDDuUS=> MYS3NkBp NUfON2hWTE2VTx?= Monk[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MYmyOVAxQTJ7NR?=
SU-DHL-4 NWmxc5NLS2WubDDWbYFjcWyrdImgRZN{[Xl? NHXFdZUxNTVyMDDuUS=> M1\mcVczKGh? MYLEUXNQ MVzk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M4DUV|I2ODB7Mkm1
SU-DHL-5 M{\PN2NmdGxiVnnhZoltcXS7IFHzd4F6 Mom3NE02ODBibl2= MWK3NkBp NWDMPGJ5TE2VTx?= M1[5eYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MUeyOVAxQTJ7NR?=
SU-DHL-6 M3zQdGNmdGxiVnnhZoltcXS7IFHzd4F6 NISxdZcxNTVyMDDuUS=> NEjTfFg4OiCq M1zTU2ROW09? NEP2WVNl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MojTNlUxODl{OUW=
SU-DHL-10 NUDG[|lXS2WubDDWbYFjcWyrdImgRZN{[Xl? NWrBXFZoOC13MECgcm0> NE\mNJM4OiCq MlnNSG1UVw>? NUXBR2ZW\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NIXTTWozPTByOUK5OS=>
RC-K8 MUXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NEDVc4MxNTVyMDDuUS=> M4WzV|czKGh? NUPicmtFTE2VTx?= MmLm[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M{fDRVI2ODB7Mkm1
OCI-Ly8 MlHUR4VtdCCYaXHibYxqfHliQYPzZZk> MYSwMVUxOCCwTR?= MofWO|IhcA>? NHPzW5RFVVOR MVjk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MYKyOVAxQTJ7NR?=
OCL-Ly18 M3XzfmNmdGxiVnnhZoltcXS7IFHzd4F6 NGj1UoExNTVyMDDuUS=> MUm3NkBp MWfEUXNQ MUDk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M{njd|I2ODB7Mkm1
OCI-Ly3 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HVW|E4Oi9{NUCvOVAxKG6P M2jrVFIwPyCm NES4R2JFVVOR MmPDbY5lfWOnczDj[YxtNWO7Y3zlJIFzemW|dDDheEB{fWJvR{Gge4l1cCCvaX7pcYFtKGOnbHyg[IVifGkEoB?= M1\3blI2ODB7Mkm1
OCI-Ly8 M1\tTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DRdVE4Oi9{NUCvOVAxKG6P NWLOdZB2Oi95IHS= MXvEUXNQ M{jxVYlv\HWlZYOgZ4VtdC2leXPs[UBienKnc4SgZZQhe3WkLVexJJdqfGhibXnubY1idCClZXzsJIRm[XSqwrC= MXOyOVAxQTJ7NR?=
SU-DHL-4 NUjCVotXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjSNVczNzJ3MD:1NFAhdk1? NITJVIgzNzdiZB?= NEPDWIdFVVOR M{HVUYlv\HWlZYOgZ4VtdC2leXPs[UBienKnc4SgZZQhe3WkLVexJJdqfGhibXnubY1idCClZXzsJIRm[XSqwrC= MUKyOVAxQTJ7NR?=
SU-DHL-10 M37ZVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;wT|E4Oi9{NUCvOVAxKG6P NXy2PYNvOi95IHS= NHXnOFdFVVOR MoXLbY5lfWOnczDj[YxtNWO7Y3zlJIFzemW|dDDheEB{fWJvR{Gge4l1cCCvaX7pcYFtKGOnbHyg[IVifGkEoB?= M3m4ZlI2ODB7Mkm1
OCI-Ly3 MXLBdI9xfG:|aYOgRZN{[Xl? M3nIO|E4Oi9{NUCgcm0> MXm3[C=> NGWwN5hFVVOR MYjpcoNz\WG|ZYOgZ4F{eGG|ZT2zM|ch[WO2aY\peJnDqHOrZ37p[olk[W62bIm= M1TXVlI2ODB7Mkm1
OCI-Ly8 NUO5R3dJSXCxcITvd4l{KEG|c3H5 NX;PUZZXOTd{L{K1NEBvVQ>? Mm\IO4Q> MVXEUXNQ NX\B[ZRUcW6lcnXhd4V{KGOjc4Dhd4UuOy95IHHjeIl3cXS7wrDzbYdvcW[rY3HueIx6 NWHLSolQOjVyMEmyPVU>
SU-DHL-4 NVe2TW82SXCxcITvd4l{KEG|c3H5 MYKxO|IwOjVyIH7N M2PVSVdl MnnoSG1UVw>? Mn6ybY5kemWjc3XzJINie3Cjc3WtN{84KGGldHn2bZR6yqC|aXfubYZq[2GwdHz5 NVLsbHZQOjVyMEmyPVU>
SU-DHL-10 MmDpRZBweHSxc3nzJGF{e2G7 M4mzN|E4Oi9{NUCgcm0> NVfCOVkzP2R? NVrrUXlkTE2VTx?= NGDOe4tqdmO{ZXHz[ZMh[2G|cHHz[U0{NzdiYXP0bZZqfHoEoIPp[45q\mmlYX70cJk> MV[yOVAxQTJ7NR?=

... Click to View More Cell Line Experimental Data

In vivo (+)-JQ1 (50 mg/kg) inhibits tumors growth in mice with NMC 797 xenografts. (+)-JQ1 (50 mg/kg) results in effacement of NUT nuclear speckles in mice with NMC 797 xenografts, consistent with competitive binding to nuclear chromatin. (+)-JQ1 (50 mg/kg) induces strong (grade 31) keratin expression in NMC 797 xenografts. (+)-JQ1 (50 mg/kg) promotes differentiation, tumor regression and prolonged survival in mice models of NMC xenografts. [1] (+)-JQ1 (50 mg/kg) results in a significant prolongation in overall survival of SCID-beige mice orthotopically xenografted after intravenous injection with MM.1S-luc+ cells compared to vehicle-treated animals. [2] (+)-JQ1 (50 mg/kg i.p.) leads to a highly significant increase in survival of mice bearing Raji xenografts. [3]

Protocol

Cell Research:

[1]

+ Expand
  • Cell lines: MC 11060 cells
  • Concentrations: ~500 nM
  • Incubation Time: 48 hours
  • Method:

    Cells are seeded into white, 384-well microtiter plates at 500 cells per well in a total volume of 50 μL media. The 797, TT and TE10 cells are grown in DMEM containing 1% penicillin/streptomycin and 10% FBS. The Per403 cells are grown in DMEM containing 1 % penicillin/streptomycin and 20% FBS. Patient-derived NMC 11060 cells are grown in RPMI with 10% FBS and 1% penicillin/streptomycin. (+)-JQ1 is delivered to microtiter assay plates by robotic pin transfer. Following a 48 hours incubation at 37℃, cells are lysed and wells are assessed for total ATP content using a commercial proliferation assay. Replicate measurements are analyzed with respect to dose and estimates of IC50 are calculated by logistic regression (GraphPad Prism).


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Mice bearing NMC 797 xenografts
  • Formulation: 5% DMSO in 5% dextrose
  • Dosages: 50 mg/kg
  • Administration: intraperitoneal injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 91 mg/mL warmed (199.12 mM)
Ethanol 91 mg/mL (199.12 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 456.99
Formula

C23H25ClN4O2S

CAS No. 1268524-70-4
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How can I reconstitute the compound for in vivo injection?

  • Answer:

    JQ1 does not dissolve in water/PBS. The vehicle we recommend is 2% DMSO+30% PEG 300+5% Tween 80+ddH2O. The compound can be dissolved in the vehicle at 5mg/ml and you can use it for IV injection.

Epigenetic Reader Domain Signaling Pathway Map

Epigenetic Reader Domain Inhibitors with Unique Features

Tags: buy (+)-JQ1 | (+)-JQ1 supplier | purchase (+)-JQ1 | (+)-JQ1 cost | (+)-JQ1 manufacturer | order (+)-JQ1 | (+)-JQ1 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID